We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.
If you're looking at dividend stocks as a source of income, obviously quality matters. But timing can play a role in how much income these investments generate for you, too.
Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more.
Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more.
Merck & Co. Inc. (NYSE:MRK ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 7:30 PM ET Company Participants Robert Davis - Chairman and CEO Dean Li - Executive VP & President of Merck Research Laboratories Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody.
Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable on Wednesday, Jan.
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration.
Merck (MRK) closed at $99.72 in the latest trading session, marking a +0.59% move from the prior day.
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million.
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
UK's Medicines and Healthcare products Regulatory Agency (MHRA) said on Tuesday it had approved Merck's therapy to treat a rare lung condition called pulmonary arterial hypertension.
The latest trading day saw Merck (MRK) settling at $98.37, representing a -1.33% change from its previous close.